- Previous Close
91.50 - Open
91.79 - Bid 89.00 x 800
- Ask 89.89 x 900
- Day's Range
89.02 - 91.93 - 52 Week Range
53.93 - 91.93 - Volume
4,015,774 - Avg. Volume
5,899,467 - Market Cap (intraday)
132.645B - Beta (5Y Monthly) 0.80
- PE Ratio (TTM)
74.38 - EPS (TTM)
1.21 - Earnings Date Jan 29, 2025 - Feb 3, 2025
- Forward Dividend & Yield --
- Ex-Dividend Date --
- 1y Target Est
97.00
Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system. It also provides technologies for diagnosing and treating coronary artery disease and aortic valve conditions; WATCHMAN FLX, a Left Atrial Appendage Closure Device; and implantable devices that monitor the heart and deliver electricity to treat cardiac abnormalities, such as cardioverter and cardiac resynchronization therapy defibrillators, MRI S-ICD systems, cardiac resynchronization therapy pacemakers, quadripolar LV leads, ICD leads, pacing leads, remote patient management systems, insertable cardiac monitor systems, and remote cardiac monitoring systems. In addition, the company offers diagnosis and treatment of rate and rhythm disorders of the heart; peripheral arterial and venous diseases; and products to diagnose, treat and ease forms of cancer. The company was incorporated in 1979 and is headquartered in Marlborough, Massachusetts.
www.bostonscientific.comRecent News: BSX
View MorePerformance Overview: BSX
Trailing total returns as of 11/22/2024, which may include dividends or other distributions. Benchmark is .
YTD Return
1-Year Return
3-Year Return
5-Year Return
Compare To: BSX
Select to analyze similar companies using key performance metrics; select up to 4 stocks.
Statistics: BSX
View MoreValuation Measures
Market Cap
132.64B
Enterprise Value
141.40B
Trailing P/E
74.38
Forward P/E
32.15
PEG Ratio (5yr expected)
1.63
Price/Sales (ttm)
8.39
Price/Book (mrq)
6.41
Enterprise Value/Revenue
8.89
Enterprise Value/EBITDA
37.95
Financial Highlights
Profitability and Income Statement
Profit Margin
11.26%
Return on Assets (ttm)
4.90%
Return on Equity (ttm)
8.92%
Revenue (ttm)
15.91B
Net Income Avi to Common (ttm)
1.79B
Diluted EPS (ttm)
1.21
Balance Sheet and Cash Flow
Total Cash (mrq)
2.5B
Total Debt/Equity (mrq)
53.72%
Levered Free Cash Flow (ttm)
1.8B